Biocryst Pharmaceuticals Inc (NASDAQ:BCRX) has a beta value of 1.06 and has seen 5.56 million shares traded in the last trading session. The company, currently valued at $2.16B, closed the last trade at $10.34 per share which meant it gained $0.37 on the day or 3.71% during that session. The BCRX stock price is -7.45% off its 52-week high price of $11.11 and 49.42% above the 52-week low of $5.23.
The consensus among analysts is that Biocryst Pharmaceuticals Inc (BCRX) is Buy stock at the moment, with a recommendation rating of 1.17. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 13 have rated it as a Hold, with 11 advising it as a Buy. 0 have rated the stock as Underweight.
Biocryst Pharmaceuticals Inc (NASDAQ:BCRX) trade information
Sporting 3.71% in the green in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the BCRX stock price touched $10.34 or saw a rise of 5.74%. Year-to-date, Biocryst Pharmaceuticals Inc shares have moved 37.50%, while the 5-day performance has seen it change -6.26%. Over the past 30 days, the shares of Biocryst Pharmaceuticals Inc (NASDAQ:BCRX) have changed 61.31%.
Wall Street analysts have a consensus price target for the stock at $16, which means that the shares’ value could jump 35.38% from current levels. The projected low price target is $7.0 while the price target rests at a high of $25.0. In that case, then, we find that the current price level is -141.78% off the targeted high while a plunge would see the stock lose 32.3% from current levels.
Biocryst Pharmaceuticals Inc (BCRX) estimates and forecasts
The company’s shares have gained 33.76% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 14.52% over the past 5 years.
BCRX Dividends
Biocryst Pharmaceuticals Inc is expected to release its next earnings report in June this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)’s Major holders
The top two institutional holders are BLACKROCK INC. with over 19.96 million shares worth more than $123.33 million. As of 2024-06-30, BLACKROCK INC. held 9.6676% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 18.77 million shares as of 2024-06-30. The firm’s total holdings are worth over $116.0 million and represent 9.0926% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . As of Dec 31, 2024 , the former fund manager holds about 3.10% shares in the company for having 6.5 shares of worth $67.16 million while later fund manager owns 5.43 shares of worth $56.1 million as of Mar 31, 2025 , which makes it owner of about 2.59% of company’s outstanding stock.
